Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Takeda Pharma launches...

    Takeda Pharma launches Rare Disease Therapies in India

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-17T09:25:54+05:30  |  Updated On 17 July 2019 9:25 AM IST
    Takeda Pharma launches Rare Disease Therapies in India

    Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease, Takeda said in a statement.


    New Delhi: Takeda Pharmaceutical Company recently said that it has launched an enzyme replacement therapy portfolio for lysosomal storage disorders (LSD) in India, expanding its range of rare disease therapies in the country.


    Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease, Takeda said in a statement.


    Read Also: Novartis buys Takeda dry eye drug Xiidrafor for $3.4 billion


    To address these, Takeda brings to the market Idursulfase for Hunter syndrome, Velaglucerase Alpha for Gaucher disease and Agalsidase Alfa for Fabry disease, it added.


    "At Takeda, we are committed to patient care by developing innovative new medicines and making existing medicines more readily available," Takeda India Country Head Vineet Singhal said.


    Japan-based Takeda focuses on research and development efforts on four therapeutic areas: oncology, gastroenterology (GI), neuroscience and rare diseases.


    Read Also: Undeterred by Sanofi stumble, Takeda takes similar path with dengue shot

    enzyme replacement therapyFabry diseasegastroenterologyGaucher diseaseHunter syndromeLSDlysosomal storage disordersneuroscienceoncologypharmapharma companypharma newsportfoliorare diseasesTakedaTakeda Pharmaceutical CompanyVineet Singhaloncology
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok